Headquartered in New Haven, CT Fiscal year ends December NASDAQ: ARVN arvinas.com
Arvinas is a clinical-stage biotechnology company that develops targeted protein degradation therapies using its proprietary PROTAC (PROteolysis TArgeting Chimera) platform. The platform harnesses the body's natural protein disposal system to selectively degrade disease-causing proteins. Together with Pfizer, Arvinas developed VEPPANU (vepdegestrant), the first FDA-approved PROTAC heterobifunctional protein degrader, indicated for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer, which has been exclusively licensed to Rigel Pharmaceuticals for global commercialization. The company's clinical pipeline spans oncology and neurology, including ARV-393 (BCL6 degrader for non-Hodgkin lymphoma), ARV-102 (LRRK2 degrader for Parkinson's disease and progressive supranuclear palsy), ARV-027 (polyQ-AR degrader for spinal and bulbar muscular atrophy/Kennedy's disease), ARV-806 (KRAS G12D degrader for solid tumors), and ARV-6723 (HPK1 degrader for immuno-oncology in advanced solid tumors). Arvinas also has preclinical programs including a novel pan-KRAS degrader. The company trades on Nasdaq under the ticker ARVN. Updated
Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Vir Biotechnology.
Here are the top analysts calls for Friday, November 25.
Tuesday's top analyst upgrades and downgrades included Apple, Chipotle Mexican Grill, Citigroup, Constellation Energy, Fastenal, JPMorgan Chase, Kroger, Livent, News Corp, Prologis, Salesforce and SunPower.
Tuesday's top analyst upgrades and downgrades included Bristol-Myers Squibb, Costco Wholesale, Dollar General, Exxon Mobil, FedEx, Horizon Therapeutics, Hyatt Hotels, Lucid, Medtronic, Micron Technology, Salesforce, Six Flags Entertainment, Tellurian and Unity Software.
Monday’s additional top analyst upgrades and downgrades were on Domino’s, iHeartMedia, Match Group, Virgin Galactic and more.
Arvinas is a clinical-stage biotechnology company that develops targeted protein degradation therapies using its proprietary PROTAC (PROteolysis TArgeting Chimera) platform. The platform harnesses the body's natural protein disposal system to selectively degrade disease-causing proteins.
24/7 Wall St.'s 12-month price target for ARVN is $13.28, rated Buy. The Wall Street consensus target is $13.93. ARVN price prediction →
